7 assets in Acute Erythroid Leukemia

Therapeutic assets addressing Acute Erythroid Leukemia, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Acute Erythroid Leukemia	Fred Hutchinson Cancer Center	P3	BBB (74)
Azacitidine Acute Erythroid Leukemia	Nanfang Hospital, Southern Medical University	P2	BB (71)
Fludarabine Acute Erythroid Leukemia	Fred Hutchinson Cancer Center	P3	BB (70)
Vorinostat Acute Erythroid Leukemia	National Cancer Institute (NCI)	P2	BB (65)
Gemtuzumab Ozogamicin Acute Erythroid Leukemia	National Cancer Institute (NCI)	P2	BB (64)
Thiotepa Acute Erythroid Leukemia	Fred Hutchinson Cancer Center	P2	CCC (53)
Dilanubicel Acute Erythroid Leukemia	Fred Hutchinson Cancer Center	P2	CCC (50)